Anticoagulant therapies represent the fundamental pillar for the prevention of thromboembolic events and the management of chronic conditions such as atrial fibrillation. Thanks to pharmacological innovation, the transition from traditional vitamin K antagonists (VKAs) to the new direct oral anticoagulants (DOACs) has radically transformed the therapeutic approach, ensuring greater safety and a better quality of life for patients.
Key Takeaways
- Transition from VKA drugs (warfarin) to DOACs (direct anticoagulants).
- Significant reduction in the risk of cerebral hemorrhages with new molecules.
- AIFA Note 97: prescription eligibility extended to General Practitioners.
How modern anticoagulant therapies work
The mechanism of action of anticoagulant therapies is based on interfering with the coagulation cascade to prevent the formation of fibrin clots. While traditional drugs like warfarin act by inhibiting the synthesis of vitamin K-dependent factors, next-generation drugs directly target specific coagulation factors, such as Factor Xa or thrombin. This molecular precision allows for a predictable anticoagulant effect without the need for constant monitoring of INR values.
The advantages of direct oral anticoagulants (DOACs)
The introduction of DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) marked a turning point in anticoagulant therapies. Clinical data validated by EMA and AIFA confirm that these molecules offer efficacy comparable or superior to classic treatments, but with a significantly better safety profile. In particular, a drastic decrease in major hemorrhagic complications has been observed, making home management much simpler for the patient and the national healthcare system.
Monitoring and safety of anticoagulant therapies
Despite their greater ease of use, anticoagulant therapies require rigorous attention to renal function and therapeutic adherence. Correct medication intake is crucial, given the short half-life of new anticoagulants compared to warfarin. In Italy, management has been further optimized by Note 97, which allows for widespread local monitoring, enabling primary care physicians to directly manage the therapeutic plan for patients with non-valvular atrial fibrillation.
